World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
76
Citations
23949
World Ranking
1888
National Ranking
919

James J. Mulé publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where James J. Mulé sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 247 publications — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

James J. Mulé D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where James J. Mulé sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 76 D-Index — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

James J. Mulé is affiliated with the University of South Florida in the United States. Their research primarily focuses on fields within Medicine and Immunology and Microbiology. Their work encompasses Oncology, Immunology, Pulmonary and Respiratory Medicine, Molecular Biology, and Surgery.

The scientist's research includes several specific topics such as Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Renal Cell Carcinoma Treatment, Immune Cells in Cancer, Bladder and Urothelial Cancer Treatments, CAR-T Cell Therapy Research, and Single-cell and Spatial Transcriptomics.

Among their recent papers are:

  • Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma, 2021, Proceedings of the National Academy of Sciences
  • Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells, 2020, Cell Metabolism
  • Epigenetic state determines the in vivo efficacy of STING agonist therapy, 2023, Nature Communications
  • Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function, 2021, Journal of Immunotherapy
  • The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy, 2022, International Journal of Radiation Oncology*Biology*Physics

Their frequent coauthors include:

  • Anders Berglund
  • Jasreman Dhillon
  • Shari Pilon-Thomas
  • Nicholas H. Chakiryan
  • Carlos Moran Segura

James J. Mulé commonly publishes in these venues:

  • Regular and Young Investigator Award Abstracts
  • The Journal of Urology
  • Journal for ImmunoTherapy of Cancer
  • Cancers
  • Journal of Clinical Oncology

Best Publications

  • Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.

    Marcin Kortylewski;Maciej Kujawski;Tianhong Wang;Sheng Wei

  • Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis.

    Yoshinori Takahashi;Domenico Coppola;Norimasa Matsushita;Hernani D. Cualing

  • Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

    Steven A. Rosenberg;James J. Mulé;Paul J. Spiess;Cheryl M. Reichert

  • Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

    James J. Mulé;Suyu Shu;Susan L. Schwarz;Steven A. Rosenberg

  • Design and Function of a Dendrimer-Based Therapeutic Nanodevice Targeted to Tumor Cells Through the Folate Receptor

    Antonio Quintana;Ewa Raczka;Lars Piehler;Inhan Lee

  • Identification of human cancers deficient in antigen processing.

    Nicholas P. Restifo;Fernando Esquivel;Yutaka Kawakami;Jonathan W. Yewdell

  • Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.

    R J Barth;J J Mulé;P J Spiess;S A Rosenberg

  • Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.

    Shari Pilon-Thomas;Krithika N. Kodumudi;Asmaa E. El-Kenawi;Shonagh Russell

  • Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses<i>in vitro</i>and<i>in vivo</i>

    Unknown

  • 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?

    Jane L. Messina;David A. Fenstermacher;Steven Eschrich;Xiaotao Qu

  • Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling

    Domenico Coppola;Michael Nebozhyn;Farah Khalil;Hongyue Dai

  • Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors.

    A. L. Asher;J. J. Mule;A.K Kasid;N. P. Restifo

  • Vaccination Of Pediatric Solid Tumor Patients with Tumor Lysate-pulsed Dendritic Cells Can Expand Specific T Cells and Mediate Tumor Regression

    James D. Geiger;Raymond J. Hutchinson;Lyndon F. Hohenkirk;Elizabeth A. McKenna

  • Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.

    A Asher;J J Mulé;C M Reichert;E Shiloni

  • The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

    J J Mulé;S Shu;S A Rosenberg

  • Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells

    Robert I. Tepper;James J. Mulé

  • Antitumor activity of recombinant interleukin 6 in mice.

    J J Mulé;J K McIntosh;D M Jablons;S A Rosenberg

  • Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.

    J. J. Mule;J. C. Yang;R. L. Afreniere;Suyu Shu

  • Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization.

    Yoshihito Kotera;Koichi Shimizu;James J. Mulé

  • NIH conference. New approaches to the immunotherapy of cancer using interleukin-2

    Steven A. Rosenberg;Michael T. Lotze;James J. Mulé

  • A Phase I Trial of Tumor Lysate-pulsed Dendritic Cells in the Treatment of Advanced Cancer

    Alfred E. Chang;Bruce G. Redman;Joel R. Whitfield;Brian J. Nickoloff

Frequent Co-Authors

Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Jeffrey S. Weber
Jeffrey S. Weber New York University
Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
Vernon K. Sondak
Vernon K. Sondak University of South Florida
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Peter A. Cohen
Peter A. Cohen Mayo Clinic
David M. Jablons
David M. Jablons University of California, San Francisco
Alfred E. Chang
Alfred E. Chang University of Michigan–Ann Arbor
Domenico Coppola
Domenico Coppola Moffitt Cancer Center
Patrick Hwu
Patrick Hwu The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related online degrees can open diverse career opportunities in healthcare and research. Many students begin by exploring online absn programs for non nurses, which are designed to quickly transition individuals without nursing backgrounds into the nursing profession.

If you’re seeking a faster entry into nursing, considering the easiest accelerated nursing programs to get into can be a practical choice. These programs often have streamlined admissions processes yet maintain essential training standards.

Another option includes enrolling in easy admission lpn programs, which provide foundational skills to work as licensed practical nurses in various clinical settings, often serving as stepping-stones for advanced degrees in immunology-related healthcare roles.

For advanced practice, consider nurse practitioner programs with easy admission. These programs prepare graduates to take on specialized roles, integrating immunology knowledge in patient care, research, and policy-making.

Choosing the right pathway depends on your background, career goals, and desired pace of education. Access to flexible online programs helps bridge the gap between immunology and practical healthcare applications.

Best Scientists Citing James J. Mulé

Trending Scientists